Raymond Urbanski, M.D., Ph.D.
Chief Executive Officer and Chairman
Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab. In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
David Cardino, CPA, MBA
Vice President of Finance
David Cardino is a financial and operational leader with over 15 years of experience in the pharmaceutical and biotech industries. Most recently, he led the finance and accounting operations of Agensys, Inc., a U.S. based oncology research center of Astellas Pharma, Inc., with a pipeline of naked and antibody-drug-conjugated (ADC) therapeutic antibodies directed at a variety of cancer indications, with annual expenses and capital investment in excess of $100M. Prior to joining Agensys, Mr. Cardino held positions of increasing responsibility at MannKind Corporation, providing strategic and financial support to the R&D and commercial organizations, and serving on the finance and pharmaceutical development leadership teams. Previous to MannKind, David held various positions at Merck & Co., Inc in areas including pharmaceutical economics, R&D portfolio evaluation, insurance and risk management, and manufacturing financial services. David began his career as an auditor with Price Waterhouse LLP. He is a certified public accountant in the state of New Jersey and holds a B.A. degree in Economics-Accounting from the College of the Holy Cross, and an M.B.A. from Duke University's Fuqua School of Business.